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A B S T R A C T   
Objective: There is high prevalence of cigarette smoking in individuals with first-episode psychosis (FEP) prior to 
psychosis onset. The purpose of the study was to determine the impact of previous tobacco use with or without 
cannabis on first psychotic experiences in FEP and the impact of this use on age of onset of symptoms, including 
prodromes. 
Methods: Retrospective analyses from the naturalistic, longitudinal, multicentre, “Phenotype-Genotype and 
Environmental Interaction. Application of a Predictive Model in First Psychotic Episodes (PEPs)” Study. The 
authors analysed sociodemographic/clinical data of 284 FEP patients and 231 matched healthy controls, and 
evaluated first psychotic experiences of patients using the Symptom Onset in Schizophrenia Inventory. 
Results: FEP patients had significantly higher prevalence of tobacco, cannabis, and cocaine use than controls. The 
FEP group with tobacco use only prior to onset (N = 56) had more sleep disturbances (42.9% vs 18.8%, P =
0.003) and lower prevalence of negative symptoms, specifically social withdrawal (33.9% vs 58%, P = 0.007) 
than FEP with no substance use (N = 70), as well as lower prevalence of ideas of reference (80.4% vs 92.4%, P =
0.015), perceptual abnormalities (46.4% vs 67.4%, P = 0.006), hallucinations (55.4% vs 71.5%, P = 0.029), and 
disorganised thinking (41.1% vs 61.1%, P = 0.010) than FEP group with previous tobacco and cannabis use (N =
144). FEP patients with cannabis and tobacco use had lower age at first prodromal or psychotic symptom (mean 
= 23.73 years [SD = 5.09]) versus those with tobacco use only (mean = 26.21 [SD = 4.80]) (P = 0.011). 
Conclusions: The use of tobacco alone was not related to earlier age of onset of a first psychotic experience, but 
the clinical profile of FEP patients is different depending on previous tobacco use with or without cannabis.  
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1. Introduction 
A higher prevalence of cigarette smoking has been reported in in-
dividuals with schizophrenia or first-episode psychosis (FEP) – at least 
twice that of the general population (Barnett et al., 2007; de Leon and 
Diaz, 2005; Kotov et al., 2010; Myles et al., 2012a). The association 
between tobacco and psychosis has been widely studied, and a causal 
relationship has been proposed between smoking and increased risk of 
psychosis (Clark et al., 2018; Gurillo et al., 2015; Hunter et al., 2020; 
Weiser et al., 2004), especially in individuals who start smoking at an 
earlier age (McGrath et al., 2016) and in individuals who are heavy 
smokers (Kendler et al., 2015; Wium-Andersen et al., 2015). Most 
studies agree that cigarette smoking generally begins before onset of 
psychosis (de Leon and Diaz, 2005; Smith et al., 2009); indeed, a meta- 
analysis by Myles et al. (2012b) reported that tobacco use precedes the 
onset of psychosis by about five years. The relationship between 
smoking and psychosis is not evidenced exclusively in the clinical pop-
ulation. In the general population, tobacco use (van Gastel et al., 2013) 
and number of cigarettes per day (Bhavsar et al., 2018) has been asso-
ciated with an increase in psychotic experiences. However, a study 
evaluating the role of tobacco use in the development of psychosis in 
individuals at clinical high risk found that smoking status did not predict 
conversion to psychosis (Ward et al., 2019). 
More controversy exists regarding whether smoking is related to age 
of onset of psychosis. While some studies have reported an association 
with an earlier onset of psychosis (Gurillo et al., 2015; McGrath et al., 
2016), others did not find a relationship when controlling for con-
founding factors such as the use of cannabis (Hickling et al., 2017; Myles 
et al., 2012a). Furthermore, other studies have reported a later onset of 
psychosis in smokers than non-smokers (Ma et al., 2010). 
Inconsistent results have also been published regarding the symp-
tomatology of smokers with psychosis. However, while there is a good 
deal of data on the effects of tobacco on symptom severity and functional 
outcomes in patients with an established diagnosis of schizophrenia or 
the non-affective psychosis spectrum (Jiang et al., 2013; Krishnadas 
et al., 2012; Ma et al., 2010; Morisano et al., 2013; Vermeulen et al., 
2019, 2018), studies on individuals with FEP are much scarcer. Some 
suggest that smokers with FEP presented greater severity of both posi-
tive and negative symptoms and worse cognition and quality of life 
(Grossman et al., 2017; Oluwoye et al., 2019), others did not find this 
relationship (Hickling et al., 2018, 2017; Sanchez-Gutierrez et al., 2018) 
or found the opposite results (Misiak et al., 2015). 
Bearing in mind the above, there are many questions related to the 
relationship between tobacco and psychosis still open to debate. Besides 
the hypothesis of considering tobacco per se as a risk factor for psy-
chosis, its impact on the phenotypic expression of the disorder and, 
consequently, the possibility of inducing a differentiated entity in terms 
of etiopathogeny, clinical features, prognosis, response to conventional 
treatments, and/or preventive interventions, remains unknown. 
To our knowledge, there are very few studies about the effects of 
tobacco on patients presenting with a first psychotic experience 
compared with those who did not use tobacco or used cannabis 
concomitantly. Therefore, the main objective of the present study is to 
describe the clinical profile of the earliest symptom of psychotic illness 
in individuals with FEP based on previous tobacco use with or without 
cannabis use. Other secondary objectives of the study are to analyse if 
there is a differential effect of tobacco on the age of onset of psychosis, 
understood as the first psychotic experience in FEP (Perkins et al., 2000), 
as well as to describe the pattern of tobacco and cannabis use in in-
dividuals with FEP compared with healthy controls. 
2. Methods 
The study was approved by the Clinical Research Ethics Committee 
of each participating site and was conducted according to the ethical 
standards of the Declaration of Helsinki and current legislation. Written 
informed consent was obtained from all participants or their legal 
guardians. 
2.1. Participants 
The sample consists of 335 individuals with FEP and 253 healthy 
controls (HC) matched by age (±10%), sex and parental socio-economic 
status, enrolled in a naturalistic, longitudinal, multicentre study 
(Phenotype-Genotype and Environmental Interaction. Application of a 
Predictive Model in First Psychotic Episodes: PEPs study) (Bernardo 
et al., 2019; Salagre et al., 2019). Methodological aspects, including 
inclusion and exclusion criteria, have been described elsewhere (Ber-
nardo et al., 2013). 
Individuals with missing data on age at first use of tobacco and 
cannabis or onset of psychosis were excluded (N = 23), as well as in-
dividuals who started using cannabis or tobacco after the earliest 
symptom (N = 1). Also, individuals under 16 years of age and patients 
who presented the earliest symptom before age 16 were excluded to 
minimize bias (mean age at onset of smoking in this sample was 15.45 
years [SD = 2.85]) (N = 28). Thus, data from 283 FEP patients and 231 
HC were analysed (see Fig. 1). After removing individuals from the 
original sample, HC were no longer matched for socioeconomic status, 
but no statistically significant differences in age and sex were detected 
[mean age: FEP 25.24 years (SD = 5.58), HC 25.22 years (SD = 5.83); 
sex: FEP 65.8% male, HC 63.2% male]. 
FEP patients were classified into 4 groups based on tobacco and/or 
cannabis use before onset of the earliest symptom, as follows: A. No 
cannabis or tobacco use (N = 70); B. Tobacco use only (N = 56); C. Both 
tobacco and cannabis use (N = 144); D. Cannabis use only (N = 13). It is 
worthy to highlight that 61 of these individuals had used cocaine at 
some point in their life, and all had an age at first cocaine use less than or 
equal (± 1 year) to the age when the earliest symptom emerged. Of 
those, 53 belonged to group C, 5 belonged to group B, 3 belonged to 
group D, and none were in group A. 
2.2. Assessment 
Baseline sociodemographic characteristics and clinical data were 
obtained from patients and controls: age, sex, marital status, living and 
work status, education level, and socioeconomic status based on 
parental sociodemographic status (Hollingshead and Redlich, 1958). 
Substance use data were collected retrospectively using the semi- 
structured interview European Adaptation of Multidimensional Assess-
ment Instrument for Drug and Alcohol Dependence (EuropAsi) (Kokkevi 
and Stefanis, 1995). Lifetime and baseline use, age at first use of tobacco, 
cannabis, and/or cocaine, and frequency or amount of tobacco and 
cannabis use were determined for the present study. Clinical psychosis 
spectrum diagnoses were established with semi-structured diagnostic 
interviews using the DSM-IV criteria (Bell, 1994). 
The first symptoms of the psychotic illness were systematic and 
retrospectively evaluated using the Symptom Onset in Schizophrenia 
(SOS) inventory (Mezquida et al., 2018; Perkins et al., 2000) by expe-
rienced psychiatrists or psychologists trained in the assessment tool. 
Using a structured clinical interview, it assesses the frequency of 
occurrence of 16 symptoms that may appear at the onset of the 
schizophrenia to dating the onset of the earliest symptom and the onset 
of psychosis, understood as the first psychotic experience (Perkins et al., 
2000). The SOS groups the symptoms in four categories: 1) General 
prodromal symptoms (dysphoric mood, sleep disturbance, ideas of 
reference, suspiciousness, thought disorder, perceptual abnormalities, 
deterioration in functioning, other - including for instance magical 
thinking, hoarding, …-); 2) Negative symptoms (social withdrawal, 
avolition, decreased expression and experience of emotion); 3) Positive 
symptoms (hallucinations and delusions); and 4) Disorganisation 
symptoms (disorganised thinking and behaviour). For each symptom, 
there are specific frequency criteria to determine its date of onset if the 
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symptom occurs. For instance, in the case of delusions the date of onset 
corresponds with the first time the individual experienced the symptom 
whereas, in the case of sleep disturbances or avolition, the date corre-
sponds when the individual started to suffer these symptoms daily or 
almost daily. Concerning the date of onset of psychosis, the SOS provides 
three estimations made by the patient, the proxy, and the interviewer, 
respectively. 
2.3. Statistical analyses 
The software package IBM SPSS Statistics for Windows, Version 23.0, 
was used for statistical analyses. Data were expressed as percentages or 
mean and standard deviation (SD). 
First, we calculated the age of onset for each symptom by subtracting 
the patient's date of birth from the symptom's onset date to determine 
the age of onset of the earliest symptom. Regarding the onset of psy-
chosis, in this paper we only employed the estimation made by the 
interviewer. 
Comparisons between FEP patients and HC characteristics and sub-
stance use patterns were made using a Chi-squared test in the case of 
categorical variables and Student's t-test for independent samples for 
continuous variables. 
In FEP patients, differences among the four substance use groups 
with respect to continuous data were analysed using an analysis of 
variance (ANOVA) and a Bonferroni post hoc test, while differences in 
prevalence of each symptom among those four groups were compared 
using a Chi-squared test. Due to a potential confounding effect of the 
concomitant use of cocaine identified in some individuals (see Fig. 1), 
we repeated the same analyses excluding them. Finally, to minimize the 
effect of potential confounders (sex, age at the onset of the earliest 
symptom, socioeconomic status, and cocaine use), a multinomial logistic 
regression model (main effects model) was carried out using substance 
use groups as the dependent variable. All variables that were statistically 
significant in the bivariate analysis were included as independent vari-
ables, and “tobacco use only” was considered the category of reference. 
In all tests, differences were considered statistically significant when P 
< 0.05. 
3. Results 
3.1. Characteristics and substance use patterns of FEP patients and 
healthy controls 
FEP patients and HC were comparable in age, sex, and marital status. 
However, differences were detected in education level (fewer than 50% 
of patients had high school or university studies versus nearly 75% of 
control subjects), in work status (16.8 vs 48.1% were employed, 
respectively), and socioeconomic status. Detailed data are presented in 
Table 1. 
Regarding substance use (Table 2), FEP patients had significantly 
Fig. 1. Flow chart of sample selection.  
Table 1 
Sociodemographic characteristics of FEP patients and healthy controls.   
FEP group (N = 283) Control group (N = 231) Statistics P 
Mean SD Mean SD 
Age (years) 25.24 5.58 25.22 5.83 t = − 0.030  0.976  
N % N %   
Sex (male) 187 65.8 146 63.2 X2 = 0.389  0.533 
Married/Living as married 36 12.7 36 15.6 X2 = 0.896  0.344 
Education level     X2 = 65.386  <0.001 
University studies 47 16.5 102 44.2   
High school studies 66 23.2 66 28.6   
Others 171 60.3 63 27.3   
Work statusa     X2 = 103.021  <0.001 
Employed 47 16.8 108 48.1   
Unemployed 98 35.1 18 7.8   
Student 103 36.9 100 43.3   
Others 31 11.1 2 0.9   
Socioeconomic status*a     X2 = 15.811  <0.001 
High or medium-high 82 29.4 96 42.1   
Medium 68 24.4 65 28.5   
Low or medium-low 129 46.2 67 29.4   
FEP, first-episode of psychosis; SD, standard deviation. 
* Parental sociodemographic status (Hollingshead and Redlich, 1958). 
a Missing data in FEP group (n = 279) and Control group (n = 228). 
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higher prevalence of tobacco, cannabis, and cocaine use than HC, both 
at the time of assessment and throughout their life (70.8%, 55.3%, 
22.2% of FEP patients vs 44.9%, 29.4%, 7.4% of HC, respectively, all P 
≤ 0.001). These differences were especially notable in the case of 
cannabis and cocaine (prevalence about two and three time higher, 
respectively). Among tobacco and cannabis smokers, there was also a 
greater intensity of use in the FEP group (both P < 0.001). However, 
there was no difference between the two groups in age at first use of the 
three substances, nor in years of regular use of cannabis and tobacco 
(detailed data in Table 2). 
3.2. Age at psychosis onset based on substance use patterns 
FEP patients distributed into the four substance use groups were 
comparatively analysed. There were statistically significant differences 
among the four groups in age at the earliest symptom (F = 2.846, P =
0.038), as those with tobacco use only were older, but not in age at onset 
of psychosis (F = 2.637, P = 0.050). In post hoc analyses, these differ-
ences were detected solely between the group with tobacco use only (B) 
and the group with tobacco and cannabis use (C) (mean age at onset of 
psychosis: B = 26.31 [SD = 4.90] vs C = 23.90 [SD = 5.19], P = 0.033; 
mean age at the earliest symptom: B = 26.21 [SD = 4.80] vs C = 23.73 
[SD = 5.09], P = 0.024) (Fig. 2). 
3.3. Profile of earliest symptom based on substance use patterns 
The prevalence of each SOS symptom in FEP patients is presented in 
the Supplementary Material. At least one general prodromal symptom 
meeting the frequency threshold criteria was present in nearly 98% of 
patients, being ideas of reference (88.7%), and suspiciousness (69.3%) 
the most common symptoms of this SOS group. While at least one 
negative symptom was present in half of the patients, at least one pos-
itive symptom was present in more than 95% of the sample. Delusions 
were the most common symptom (95.1%). No difference was found in 
the initial clinical presentation based on sex (Supplementary Table S1). 
Table 3 shows the prevalence of each symptom based on substance 
use groups. There were no statistically significant differences between A 
(no cannabis or tobacco use) and C (tobacco & cannabis use). Also, no 
statistically significant differences were detected between D (cannabis 
only use) and any of the other three groups. However, differences were 
detected between group B (tobacco only user) vs group A on the one 
hand and vs group C on the other. Thus, compared to individuals with no 
substance use (group A), tobacco only users presented sleep distur-
bances much more frequently (more than 40% vs less than 20%) and 
negative symptoms, specifically social withdrawal, less frequently. On 
the other hand, patients with use of both substances (group C), more 
frequently presented ideas of reference, perceptual abnormalities, 
Table 2 
Substance use data in FEP patients and healthy controls.   
FEP group (N = 283) Control group (N = 231) Statistics P 
Tobacco  
N % N %   
Lifetime users 201 70.8 106 45.9 X2 = 32.771 <0.001 
Baseline users 191 67.3 97 42 X2 = 32.981 <0.001 
Daily users 172 60.6 71 30.7   
Sporadic users 19 6.7 26 11.3    
Mean SD Mean SD   
Cigarettes/day 14.55 8.02 9.42 6.29 t = − 4.841 <0.001 
Age at first use 15.44 2.85 15.47 2.87 t = 0.084 0.933 
Years of regular use [at least 1 year] 7.98 [n = 187] 4.89 8.69 
[n = 83] 
6.29 t = 1.002 0.317  
Cannabis  
N % N %   
Lifetime users 157 55.3 68 29.4 X2 = 34.585 <0.001 
Baseline users 133 46.8 48 20.8 X2 = 37.930 <0.001 
Daily users 84 29.6 8 3.5   
Weekly users 16 5.6 13 5.6   
Monthly users 9 3.2 18 7.8   
Sporadic users 24 8.5 9 3.9    
Mean SD Mean SD   
Age at first use 16.19 3.00 16.51 1.86 t = 0.823 0.411 
Years of regular use [at least 1 year] 5.68 [n = 132] 4.21 5.46 [n = 28] 4.21 t = − 0.248 0.804  
Cocaine  
N % N %   
Lifetime users 61 21.5 17 7.4 X2 = 21.334 <0.001 
Baseline users 39 13.7 11 4.8 X2 = 11.694 0.001  
Mean SD Mean SD   
Age at first use 19.14 4.04 19.65 3.22 t = 0.474 0.637 
FEP, first-episode of psychosis; SD, standard deviation. 
Fig. 2. Age at psychosis onset based on substance use groups.  
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hallucinations, and disorganised thinking, compared with those who 
used tobacco only. 
When the 61 subjects who had used cocaine at some point in their life 
(but started the use prior to the onset of the earliest symptom) were 
excluded from these analyses, identical results were obtained for dif-
ferences in the prevalence of sleep disturbances (X2 = 7.344, P = 0.025), 
negative symptoms (X2 = 6.671, P = 0.036), social withdrawal (X2 =
7.446, P = 0.024), disorganised thinking (X2 = 7.588, P = 0.023), and 
ideas of reference (X2 = 5.227, P = 0.073; B vs C: X2 = 5.213, P = 0.022). 
However, statistically significant differences disappeared for prevalence 
of hallucinations and perceptual abnormalities (data not shown). 
Results from the multinomial regression analysis, using group B as 
category of reference, showed that differences previously detected be-
tween the group B (“tobacco only”) and group A (“non cannabis or to-
bacco”), sleep disturbances (OR = 0.133–0.733) and social withdrawal 
(OR = 1.085–5.248), remained statistically significant in the model. On 
the other hand, the model exploring differences between the group B 
and group C (“tobacco & cannabis”) retained the variables disorganised 
thinking (OR = 1.173–5.194) and ideas of reference (OR =
1.206–12.262), along with cocaine use (OR = 3.355–33.483), male sex 
(OR = 0.132–0.608) and age at first symptom (OR = 0.830–0.956). 
More statistical data (B, OR, and CI 95%) is presented on Table S2 of 
Supplementary Material. 
4. Discussion 
Regarding the main objective of this study, we observed a differential 
clinical profile of the earliest symptom of psychosis in our FEP patients 
who used tobacco only before the development of symptoms, compared 
with the no substance use group and the cannabis and tobacco use 
group. In comparison with patients with no tobacco or cannabis use, 
patients who used tobacco only presented sleep disturbances more 
frequently and negative symptoms, specifically social withdrawal, less 
frequently. On the other hand, in comparison with both tobacco and 
cannabis users, tobacco only users showed a lower prevalence of ideas of 
reference, perceptual abnormalities, hallucinations, and disorganised 
thinking. Furthermore, those patients who used tobacco only experi-
enced the earliest symptom at an older age than those who used tobacco 
and cannabis concomitantly. This difference in age was not found be-
tween either of these two groups and the group of patients who did not 
use tobacco or cannabis. Also, we did not find any difference between 
the group of cannabis only and the other three groups, although this can 
be explained by the small sample size of this group (n = 13). 
In this regard, tobacco alone does not seem to be related to an earlier 
age of onset of the first psychotic episode without concomitant use of 
cannabis, as other studies have already reported (Hickling et al., 2017; 
Myles et al., 2012a). Furthermore, our study suggests that tobacco use 
also does not influence age of onset of the earliest symptom of psychosis 
when compared with those who do not use. 
Our results confirm what has already been published, i.e. that FEP 
patients use both tobacco and cannabis with greater frequency and in-
tensity than the general population of the same age and sex (Grossman 
et al., 2017; Lally et al., 2019; Pauselli et al., 2018), with no difference in 
relation to age of onset of this use. Our results for current smoking 
prevalence (67.3%) and lifetime use (70.8%) in our FEP sample do not 
reach the rates of 78% reported by Lally et al. (2019), but are higher 
than the rates of 58.9% and 57%, respectively, reported by two meta- 
analyses (Gurillo et al., 2015; Myles et al., 2012b). 
4.1. Symptom profiles in FEP patients 
In the initial phase of the illness, almost all of our FEP patients have 
had at least one general prodromal symptom of significant persistence, 
and more than 95% have experienced one positive symptom. Addi-
tionally, about half have experienced at least some negative symptom-
atology from the early stages, which is striking considering that not all 
Table 3 
Differences in frequency of symptoms at onset in FEP patients by substance use group.   
A. Non tobacco or cannabis users (N =
70) 
B. Tobacco only 
users 
(N = 56) 
C. Tobacco & cannabis users (N =
144) 
D. Cannabis only 
users 
(N = 13) 
P* 
N % N % N % N %  
General prodromal symptoms  68  98.6  56  100.0  139  96.5  13  100  0.407 
Dysphoric mood  17  24.6  17  30.4  33  22.9  5  38.5  0.498 
Sleep disturbance  13  18.8  24  42.9  42  29.2  4  30.8  0.035a 
Ideas of reference  60  87.0  45  80.4  133  92.4  12  92.3  0.104b 
Suspiciousness  50  72.5  38  67.9  100  69.4  8  61.5  0.862 
Thought disorder  43  62.3  27  48.2  87  60.4  8  61.5  0.373 
Perceptual abnormalities  39  56.5  26  46.4  97  67.4  9  69.2  0.039c 
Deterioration in functioning  20  29.0  12  21.4  45  31.3  5  38.5  0.480 
Others (obsessions, etc.)  9  13.6  12  21.4  30  20.8  4  33.3  0.368 
Negative symptoms  42  60.9  21  37.5  71  51.4  6  46.2  0.075d 
Social withdrawal  40  58.0  19  33.9  69  47.9  5  38.5  0.055e 
Avolition  6  8.7  5  8.9  20  13.9  2  15.4  0.602 
Decreased expression of emotions  9  13.0  4  7.1  14  9.7  3  23.1  0.336 
Decreased experience of emotions  8  11.6  4  7.1  18  12.5  3  23.1  0.416 
Positive symptoms  68  97.1  51  91.1  140  97.2  13  100  0.171 
Hallucinations  41  58.6  31  55.4  103  71.5  9  69.2  0.099f 
Delusions  65  94.2  51  91.1  139  96.5  13  100  0.344 
Disorganisation symptoms  40  58.0  29  51.8  92  63.9  9  69.2  0.283 
Disorganised thinking  34  49.3  23  41.1  88  61.1  9  69.2  0.037g 
Disorganised behaviour  31  44.9  21  37.5  72  50.0  8  61.5  0.288 
Post hoc analyses (chi-squared test): 
a Sleep disturbances: A vs B, P = 0.003; B vs C, P = 0.064. 
b Ideas of reference: B vs C, P = 0.015. 
c Perceptual abnormalities: B vs C, P = 0.006. 
d Negative symptoms: A vs B, P = 0.009. 
e Social withdrawal: A vs B, P = 0.007. 
f Hallucinations: B vs C, P = 0.029; A vs C, P = 0.058. 
g Disorganised thinking: B vs C, P = 0.010; B vs D, P = 0.067. 
* Differences between groups were tested for statistical significance using chi-squared test (degrees of freedom = 3). 
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FEP patients, including those with affective and non-affective psychosis, 
progress to a diagnosis of schizophrenia. 
To our knowledge, this is the first study that explores differential 
clinical profiles of the earliest symptoms of psychosis in FEP patients 
based on patterns of previous substance use. One of the most important 
findings of this study is that patients with FEP and a history of tobacco 
smoking had an increased prevalence of sleep disturbances as a general 
prodromal symptom, reaching 43% in comparison with rates of less than 
20% in non-smoking patients. Many studies have associated sleep 
problems with an increased risk of psychotic experience in clinical and 
non-clinical populations (Davies et al., 2017; Lally et al., 2019; Pauselli 
et al., 2018). These findings lead us to speculate whether sleep distur-
bances may have played an important role in the previous findings 
relating tobacco to an increased risk of developing psychosis (Lunsford- 
Avery et al., 2017; Reeve et al., 2019). 
However, compared with patients who used cannabis concomitantly, 
FEP patients who used tobacco only showed less frequent positive 
symptoms, such as hallucinations, and disorganised thinking, and less 
frequent general prodromes, such as perceptual abnormalities or ideas 
of reference. Furthermore, some of the studies conducted to date have 
not found a significant relationship with clinical patterns of psychotic 
symptoms in tobacco smoking FEP patients (Hickling et al., 2018, 2017). 
This data contrasts with the findings of other authors who have reported 
that the effect of tobacco on the onset of psychosis is causally related and 
is independent of cannabis (Gurillo et al., 2015; Hunter et al., 2020; 
McGrath et al., 2016). Nevertheless, it should be mentioned that when 
we repeated our analyses excluding patients who had used cocaine, 
differences in the prevalence of perceptual abnormalities and halluci-
nations disappeared, but psychopathological thoughts (disorganised 
thinking and ideas of reference) were maintained and were more prev-
alent in patients using both substances. There were no changes when 
comparing patients with and without tobacco use, as is logical for the 
few that were excluded from these groups. Identical results were ob-
tained in the regression analysis that adjusted for cocaine use, sex, age at 
first symptoms and socioeconomic status. 
Our findings also show lower prevalence of negative symptoms, such 
as social withdrawal, in FEP patients with tobacco use only comparing 
with those with non-substance use, in keeping with prior research sug-
gesting that smoking is related to less severity of negative symptom-
atology in patients with psychosis (Jiang et al., 2013; Misiak et al., 
2015), but in contrast to other authors (Oluwoye et al., 2019; Vermeulen 
et al., 2018). Although we cannot conclude that this is a causal effect, it 
should be noted that every patient in our sample started smoking before 
onset of any general prodromal or negative symptom. Surprisingly, we 
found no difference in the prevalence of negative symptoms when 
comparing patients with no substance use with those who used tobacco 
plus cannabis, in contrast to Ferraro et al. (2020), who detected that 
lifetime cannabis use could be associated with less social withdrawal. 
This study is part of a large multicentre study in patients with the 
first episode of psychosis; however, some limitations should be noted. 
One of the main limitations is that the data related to the onset of sub-
stance use and the earliest symptom of psychosis were collected retro-
spectively in a structured interview with patient and family, with the 
possibility of potential memory bias. Instead, a prospective study would 
allow us to draw conclusions about a causal relationship. Also, while the 
SOS inventory can identify a variety of early symptoms of psychosis, it 
does not include premorbid cognitive dysfunction that could have an 
effect on the results obtained. On the other hand, current and prior 
substance use were self-reported, and no laboratory test was used to 
confirm this. Another limitation would be the lack of data on the use of 
other drugs such as stimulants prior to the development of symptoms, 
which could interfere, like cocaine use, in the results obtained in this 
study (Bramness and Rognli, 2016). Nevertheless, it should be noted that 
we observed a low prevalence (less than 5%) in the use of stimulants at 
baseline assessment of patients with FEP. 
Moreover, the current study has important strengths. As a 
naturalistic and multicentre study, a large number of deeply phenotyped 
sample of FEP patients from different regions in Spain were included in 
this study; this sample may be considered representative of this popu-
lation and potentially generalisable. Furthermore, the group of healthy 
controls has been matched to our study group, achieving a comparable 
group in age and sex. To our knowledge, this is the first study analysing 
differences in prodromes of FEP patients based on previous substance 
use. In addition, although cannabis use has often been considered a 
confounding factor in previous research on tobacco and FEP, one 
strength of our study is the comparative analyses between a group of 
patients with tobacco use only and patients with concomitant cannabis 
and tobacco use. Another strength is the use of a structured interview to 
assess first psychotic experience (first psychotic and general symptoms), 
that collects information from both patients and relatives or caregivers. 
5. Conclusions 
In summary, in our study the use of tobacco alone was associated 
with a higher prevalence of specific general prodromal symptoms of 
psychosis such as sleep disturbances, while tobacco plus cannabis use 
was associated with psychopathological thoughts as ideas of reference 
and disorganised thinking. Thus, our results provide evidence against 
previous findings that relate tobacco alone to the onset of psychosis, as 
this was only found for concomitant tobacco and cannabis users. How-
ever, despite this negative result, it is still important to monitor and 
apply smoking prevention strategies in adolescents because cigarette use 
is associated with greater subsequent initiation of other drugs such as 
cannabis (Tullis et al., 2003), indirectly advancing the age of onset of 
symptoms. Of note, there was a high concurrence of tobacco and 
cannabis use; in fact, nearly 75% of the cigarette smokers among our 
FEP patients had used cannabis. In this sense, and given the high prev-
alence of tobacco use in our FEP patients, we propose smoking cessation, 
not only in patients with established mental illness (Anthenelli et al., 
2016; Garcia-Portilla et al., 2016; Sarramea et al., 2019), but from the 
early stages. 
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